Pharmaron Beijing Co., Ltd. Class H (DE:17Q1)
FRANKFURT:17Q1
Holding DE:17Q1?
Track your performance easily

Pharmaron Beijing Co., Ltd. Class H (17Q1) Income Statement

0 Followers

Pharmaron Beijing Co., Ltd. Class H Income Statement

Last quarter (Q4 2022), Pharmaron Beijing Co., Ltd. Class H's total revenue was ¥2.86B, an increase of 33.67% from the same quarter last year. In Q4, Pharmaron Beijing Co., Ltd. Class H's net income was ¥413.50M. See Pharmaron Beijing Co., Ltd. Class H’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19
Total Revenue
¥ 10.27B¥ 10.27B¥ 7.44B¥ 5.13B¥ 3.76B
Cost of Revenue
¥ 6.50B¥ 6.50B¥ 4.76B¥ 3.21B¥ 2.42B
Gross Profit
¥ 3.77B¥ 3.77B¥ 2.68B¥ 1.92B¥ 1.33B
Operating Expense
¥ 2.02B¥ 2.02B¥ 1.15B¥ 838.94M¥ 630.23M
Operating Income
¥ 1.75B¥ 1.75B¥ 1.52B¥ 1.08B¥ 704.14M
Net Non Operating Interest Income Expense
¥ -134.63M¥ -134.63M¥ -20.05M¥ 48.86M¥ -74.09M
Other Income Expense
-----
Pretax Income
¥ 1.67B¥ 1.67B¥ 1.91B¥ 1.32B¥ 632.55M
Tax Provision
¥ 314.25M¥ 314.25M¥ 290.92M¥ 172.38M¥ 101.88M
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
¥ 1.37B¥ 1.37B¥ 1.66B¥ 1.17B¥ 547.19M
Basic EPS
-----
Diluted EPS
-----
Basic Average Shares
-----
Diluted Average Shares
-----
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
--¥ 136.48M--
Total Expenses
¥ 8.52B¥ 8.52B¥ 5.92B¥ 4.05B¥ 3.05B
Net Income From Continuing And Discontinued Operation
¥ 1.37B¥ 1.37B¥ 1.66B¥ 1.17B¥ 547.19M
Normalized Income
¥ 1.45B¥ 1.44B¥ 1.75B¥ 1.08B¥ 540.43M
Interest Expense
¥ 167.31M¥ 167.31M¥ 83.07M¥ 23.85M¥ 82.48M
EBIT
¥ 1.83B¥ 1.83B¥ 1.99B¥ 1.34B¥ 715.03M
EBITDA
¥ 1.83B¥ 2.53B¥ 2.49B¥ 1.72B¥ 1.03B
Currency in CNY

Pharmaron Beijing Co., Ltd. Class H Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis